Sali Lapo, Ventura Leonardo, Mascalchi Mario, Falchini Massimo, Mantellini Paola, Delsanto Silvia, Milani Stefano, Zappa Marco, Grazzini Grazia
Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence.
Cancer Prevention and Research Institute (ISPO), Screening Unit, Florence.
Eur J Cancer Prev. 2018 Mar;27(2):105-109. doi: 10.1097/CEJ.0000000000000284.
The aim of this study was to evaluate the participation and yield of the faecal immunochemical test (FIT) in nonattendees for computed tomography colonography (CTC) or optical colonoscopy (OC) screening, in the setting of a randomized trial. In the SAVE trial, 16087 individuals were randomly assigned and invited to one of four interventions for colorectal cancer screening: (i) biennial FIT for three rounds; (ii) reduced-preparation CTC; (iii) full-preparation CTC; and (iv) OC. Nonattendees of reduced-preparation CTC, full-preparation CTC and OC groups were invited to FIT. Here, we analysed the participation rate and the detection rate for cancer or advanced adenoma (advanced neoplasia) of FIT among nonattendees for reduced-preparation CTC, full-preparation CTC and OC. Nonattendees were 1721 of 2395 (71.9%) eligible invitees in the reduced-preparation CTC group, 1818 of 2430 (74.8%) in the full-preparation CTC group and 883 of 1036 (85.2%) in the OC group. Participation rates for FIT were 20.2% (347/1721) in nonattendees for reduced-preparation CTC, 21.4% (389/1818) in nonattendees for full-preparation CTC and 25.8% (228/883) in nonattendees for OC. Differences between both CTC groups and the OC group were statistically significant (P≤0.01), whereas the difference between reduced-preparation and full-preparation CTC groups was not statistically significant (P=0.38). The detection rate of FIT was not statistically significantly different among nonattendees for reduced-preparation CTC (0.9%; 3/347), nonattendees for full-preparation CTC (1.8%; 7/389) and nonattendees for OC (1.3%; 3/228) (P>0.05). Offering FIT to nonattendees for CTC or OC increases the overall participation in colorectal cancer screening and enables the detection of additional advanced neoplasia.
本研究的目的是在一项随机试验的背景下，评估粪便免疫化学试验（FIT）在未参加计算机断层扫描结肠成像（CTC）或光学结肠镜检查（OC）筛查的人群中的参与情况及检测率。在SAVE试验中，16087名个体被随机分配并受邀参加四种结直肠癌筛查干预措施之一：（i）每两年进行三轮FIT；（ii）低剂量准备的CTC；（iii）全剂量准备的CTC；以及（iv）OC。低剂量准备的CTC组、全剂量准备的CTC组和OC组的未参与者被邀请参加FIT。在此，我们分析了低剂量准备的CTC组、全剂量准备的CTC组和OC组的未参与者中FIT对癌症或高级别腺瘤（高级别瘤变）的参与率和检测率。低剂量准备的CTC组中，2395名符合条件的受邀者中有1721名未参与者（71.9%），全剂量准备的CTC组中，2430名中有1818名（74.8%），OC组中，1036名中有883名（85.2%）。低剂量准备的CTC组未参与者中FIT的参与率为20.2%（347/1721），全剂量准备的CTC组未参与者中为21.4%（389/1818），OC组未参与者中为25.8%（228/883）。两个CTC组与OC组之间的差异具有统计学意义（P≤0.01），而低剂量准备的CTC组与全剂量准备的CTC组之间的差异无统计学意义（P = 0.38）。低剂量准备的CTC组未参与者中FIT的检测率（0.9%；3/347）、全剂量准备的CTC组未参与者中（1.8%；7/389）和OC组未参与者中（1.3%；3/228）之间无统计学显著差异（P >
